News & Insights

We were glad to squeeze in one more conference before last year came to a close: Antibody Engineering and Therapeutics (AET) 2023. AET is always a great chance to connect with friends and colleagues in the biotechnology sphere who we don’t get to see in person very often. This time, I was accompanied by Michael Trang and Jennifer Somera, two of Antibody Solutions’ esteemed project managers. 

Here at Antibody Solutions, we believe that starting with the best possible input will yield the best possible output. A critical input for any antibody discovery program is the immunogen; i.e., what will be administered to the host animal to raise an antibody response? While it may seem complex, intact cells bearing your target antigen may be the best input. We explore that subject in this blog post through a series of frequently asked questions from our clients.

Antibody Solutions is doing its part to respond to the COVID-19 pandemic, including original research, tool discovery, and participation in in-house and client-sponsored discovery programs. In this new blog series, we examine questions such as: What are the potential targets to treat COVID-19 and its sequelae, and what are the strategies and tools to discover drugs to treat the disease?

Accessing the Untapped Potential of 33% of Human IgG

Agreement Provides for Easy Access to the Transgenic H2L2 Harbour Mice™ Platform with Antibody Solutions’ Discovery and Development Services

When you think about the rat IgG production and purification process (especially IgG2a), what words often come to mind? If you’re like most researchers, it’s probably a combination of these: frustration, missed timelines, low purity, and poor recovery.